{
  "company": {
    "name": "Century Therapeutics",
    "website": "https://centurytx.com/",
    "record": "https://startuphistory.org/c/centurytx.com"
  },
  "status": null,
  "history_since": "2019-08-05T15:17:15.000Z",
  "baseline": {
    "snapshot_id": "652f276ac0de7d41333757b24baa695ac97fbe70302868e6e24dc2e5af7cdf39",
    "observed_at": "2019-08-05T15:17:15.000Z",
    "headline": null,
    "description": "Century’s gene edited immune effector cell therapies (T cell and NK cells) based on induced pluripotent stem cells (iPSC) are designed to target heme and solid tumors.",
    "evidence": "https://web.archive.org/web/20190805151715/https://www.centurytx.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-05T12:31:58.717Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2026-11-05T12:31:58.717Z",
      "variants": [
        {
          "headline": "Limitless Potential. Precision Design. Enduring Impact.",
          "subhead": "Century Therapeutics is on a mission to develop innovative allogeneic, iPSC-derived NK and T cell therapies that are more effective, tolerable, accessible, and affordable versus existing cells therapi",
          "observed_at": "2022-01-19T10:14:39.000Z",
          "evidence": "https://web.archive.org/web/20220119101439/https://www.centurytx.com:443/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Limitless Potential. Precision Design. Enduring Impact.",
          "subhead": "Century Therapeutics is on a mission to develop innovative allogeneic, iPSC-derived NK and T cell therapies that are more effective, tolerable, accessible, and affordable versus existing cells therapi",
          "observed_at": "2022-07-15T12:39:45.000Z",
          "evidence": "https://web.archive.org/web/20220715123945/https://www.centurytx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Limitless Potential. Precision Design. Enduring Impact.",
          "subhead": "Century Therapeutics is on a mission to develop innovative allogeneic, iPSC-derived NK and T cell therapies that are more effective, tolerable, accessible, and affordable versus existing cells therapi",
          "observed_at": "2023-09-29T03:17:18.000Z",
          "evidence": "https://web.archive.org/web/20230929031718/https://www.centurytx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Limitless Potential. Precision Design. Enduring Impact.",
          "subhead": "Century Therapeutics is on a mission to develop innovative allogeneic, iPSC-derived NK and T cell therapies that are more effective, tolerable, accessible, and affordable versus existing cells therapi",
          "observed_at": "2024-01-04T09:00:45.000Z",
          "evidence": "https://web.archive.org/web/20240104090045/https://www.centurytx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Limitless Potential. Precision Design. Enduring Impact.",
          "subhead": "Century Therapeutics is on a mission to develop innovative allogeneic, iPSC-derived NK and T cell therapies that are more effective, tolerable, accessible, and affordable versus existing cells therapi",
          "observed_at": "2025-01-12T04:27:55.000Z",
          "evidence": "https://web.archive.org/web/20250112042755/https://www.centurytx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Limitless Potential. Precision Design. Enduring Impact.",
          "subhead": "Century Therapeutics is on a mission to develop innovative allogeneic, iPSC-derived NK and T cell therapies that are more effective, tolerable, accessible, and affordable versus existing cells therapi",
          "observed_at": "2025-07-10T10:33:59.000Z",
          "evidence": "https://web.archive.org/web/20250710103359/https://www.centurytx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Limitless Potential. Precision Design. Enduring Impact.",
          "subhead": "Century Therapeutics is on a mission to develop innovative allogeneic, iPSC-derived NK and T cell therapies that are more effective, tolerable, accessible, and affordable versus existing cells therapi",
          "observed_at": "2026-01-20T08:55:42.000Z",
          "evidence": "https://web.archive.org/web/20260120085542/https://www.centurytx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Limitless Potential. Precision Design. Enduring Impact.",
          "subhead": "Century Therapeutics is on a mission to develop innovative allogeneic, iPSC-derived NK and T cell therapies that are more effective, tolerable, accessible, and affordable versus existing cells therapi",
          "observed_at": "2026-05-01T16:30:39.000Z",
          "evidence": "https://web.archive.org/web/20260501163039/https://www.centurytx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Limitless Potential. Precision Design. Enduring Impact.",
          "subhead": "Century Therapeutics is on a mission to develop innovative allogeneic, iPSC-derived NK and T cell therapies that are more effective, tolerable, accessible, and affordable versus existing cells therapi",
          "observed_at": "2026-07-23T00:24:33.000Z",
          "evidence": "https://web.archive.org/web/20260723002433/https://www.centurytx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Limitless Potential. Precision Design. Enduring Impact.",
          "subhead": "Century Therapeutics is on a mission to develop innovative allogeneic, iPSC-derived NK and T cell therapies that are more effective, tolerable, accessible, and affordable versus existing cells therapi",
          "observed_at": "2026-08-03T16:04:32.000Z",
          "evidence": "https://web.archive.org/web/20260803160432/https://www.centurytx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Limitless Potential. Precision Design. Enduring Impact.",
          "subhead": "Century Therapeutics is on a mission to develop innovative allogeneic, iPSC-derived NK and T cell therapies that are more effective, tolerable, accessible, and affordable versus existing cells therapi",
          "observed_at": "2026-10-27T18:51:00.000Z",
          "evidence": "https://web.archive.org/web/20261027185100/https://www.centurytx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Limitless Potential. Precision Design. Enduring Impact.",
          "subhead": "Century Therapeutics is on a mission to develop innovative allogeneic, iPSC-derived NK and T cell therapies that are more effective, tolerable, accessible, and affordable versus existing cells therapi",
          "observed_at": "2026-11-05T12:31:58.717Z",
          "evidence": "https://www.centurytx.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Limitless Potential. Precision Design. Enduring Impact.",
      "subhead": "Century Therapeutics is on a mission to develop innovative allogeneic, iPSC-derived NK and T cell therapies that are more effective, tolerable, accessible, and affordable versus existing cells therapi",
      "from": "2022-01-19T10:14:39.000Z",
      "to": "2026-11-05T12:31:58.717Z",
      "captures": 12,
      "evidence": "https://www.centurytx.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2022-01-19T10:14:39.000Z",
          "to": "2026-11-05T12:31:58.717Z"
        }
      },
      "current": true
    }
  ],
  "changes": [],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Century Therapeutics” company record, https://startuphistory.org/c/centurytx.com"
}